ARK Invest's position in IONS, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 937,118 | $25.6M | 1.30% | #26 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | ARKG | Buy | Added | 100,241 | $4.5M |
| 2026-09-14 | ARKG | Buy | Added | 166,585 | $8.6M |
| 2026-08-19 | ARKG | Buy | Added | 18,499 | $1.1M |
| 2026-08-18 | ARKG | Buy | Added | 26,246 | $1.6M |
| 2026-08-17 | ARKG | Buy | Added | 6,839 | $401K |
| 2026-07-14 | ARKG | Buy | Added | 49,003 | $2.7M |
| 2026-07-13 | ARKG | Buy | Added | 66,277 | $3.8M |
| 2026-07-10 | ARKG | Buy | Added | 28,034 | $1.6M |
| 2026-07-09 | ARKG | Buy | Added | 105,364 | $6.8M |
| 2026-03-25 | ARKG | Sell | Trimmed | 14,550 | $1.1M |
| 2026-03-13 | ARKG | Sell | Trimmed | 7,220 | $514K |
| 2026-03-12 | ARKG | Sell | Trimmed | 43,533 | $3.1M |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary…
See IONS's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open IONS on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.